Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
暂无分享,去创建一个
[1] René Bernards,et al. A progression puzzle. , 2002, Nature.
[2] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[3] Annuska M Glas,et al. Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[4] R. Campanini,et al. Breast cancer metastases are molecularly distinct from their primary tumors , 2008, Oncogene.
[5] I. Petersen,et al. Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer. , 2004, Neoplasia.
[6] K. Hatakeyama,et al. Heterogeneity of p53 Mutational Status in Esophageal Squamous Cell Carcinoma , 1998, Japanese journal of cancer research : Gann.
[7] J. Peterse,et al. Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.
[8] Chunlei Wu,et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis , 2004, Cancer.
[9] J R Siewert,et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. , 2000, The American journal of pathology.
[10] S. Veronese,et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Rabes,et al. K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.
[12] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[13] D. Smith,et al. p53 Mutations in primary colorectal adenocarcinomas and liver metastases , 1996, The British journal of surgery.
[14] T. Stephenson,et al. Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization , 2003, Genes, chromosomes & cancer.
[15] J. Andersen,et al. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases , 2007, Breast Cancer Research and Treatment.
[16] H. Dai,et al. No common denominator for breast cancer lymph node metastasis , 2005, British Journal of Cancer.
[17] P. Bachellier,et al. Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes , 2007, International journal of cancer.
[18] John Cairns,et al. Mutation selection and the natural history of cancer , 1975, Nature.
[19] Liang Cheng,et al. Clonal relationships between epidermotropic metastatic melanomas and their primary lesions: a loss of heterozygosity and X-chromosome inactivation-based analysis , 2007, Modern Pathology.
[20] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[21] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[22] H. Höfler,et al. Molecular Genetic Changes in Metastatic Primary Barrett’s Adenocarcinoma and Related Lymph Node Metastases: Comparison with Nonmetastatic Barrett’s Adenocarcinoma , 2000, Modern Pathology.
[23] F. Al-Mulla,et al. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases , 1999, Genes, chromosomes & cancer.
[24] A. Russo,et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. , 2004, Biochemical and biophysical research communications.
[25] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[26] M. Loda,et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. , 1995, Oncogene.
[27] B. Haddad,et al. Patterns of DNA copy number changes in sentinel lymph node breast cancer metastases , 2008, Cytogenetic and Genome Research.
[28] Wei Zhang,et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients , 2007, Breast Cancer Research and Treatment.
[29] Sabine Riethdorf,et al. Review: Biological relevance of disseminated tumor cells in cancer patients , 2008, International journal of cancer.
[30] A. Chakraborty,et al. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.
[31] Martin A. Nowak,et al. Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.
[32] Liang Cheng,et al. Clonal origin of lymph node metastases in bladder carcinoma , 2005, Cancer.
[33] F. Holstege,et al. Maintenance of head and neck tumor gene expression profiles upon lymph node metastasis. , 2006, Cancer research.
[34] R. Eils,et al. Systemic spread is an early step in breast cancer. , 2008, Cancer cell.
[35] J. Shih,et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] S. Petersen,et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases , 2002, Virchows Archiv.
[37] S. Rha,et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer , 2007, International journal of cancer.
[38] C. Klein,et al. Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.
[39] F. Bosman,et al. Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph‐node metastases , 1997, International journal of cancer.
[40] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[41] I. Petersen,et al. Chromosomal Alterations in Lung Metastases of Colorectal Carcinomas: Associations with Tissue Specific Tumor Dissemination , 2005, Clinical & Experimental Metastasis.
[42] A. Ullrich,et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. , 2008, Cancer cell.
[43] R. Eils,et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[44] M W Kattan,et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] K. Lundholm,et al. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection , 2001, Cancer.
[46] T. Lynch. The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[47] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[48] K. Hunter,et al. Host genetics influence tumour metastasis , 2006, Nature Reviews Cancer.
[49] A. Ardizzoni,et al. Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[50] D. Tarin,et al. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: Clinical implications , 2007, Molecular oncology.
[51] I. Floriani,et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.
[52] T. Ragg,et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Izbicki,et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] S. Rodenhuis,et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.
[55] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[56] Liang Cheng,et al. Genetically Heterogeneous and Clonally Unrelated Metastases May Arise in Patients With Cutaneous Melanoma , 2007, The American journal of surgical pathology.
[57] R. Weinberg,et al. Adaptation versus selection: the origins of metastatic behavior. , 2007, Cancer research.
[58] A. Schäffer,et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.
[59] C. Antonescu. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas , 2008, Modern Pathology.
[60] B. Deyarmin,et al. The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer , 2008, Annals of Surgical Oncology.
[61] R. Eils,et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.
[62] J. Luketich,et al. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. , 2002, Cancer research.
[63] Chi-Hung Lin,et al. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases—An analysis by comparative genomic hybridization , 2005, Genes, chromosomes & cancer.
[64] F. Al-Mulla,et al. Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality , 1998, The Journal of pathology.
[65] E. Stathopoulos,et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.
[66] G. Schlimok,et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.